Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

(November 9, 2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading


FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

(November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading


Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

(November 1, 2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology... Continue Reading


Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

(October 30, 2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer... Continue Reading


Radius Health Receives FDA Fast Track Designation for Elacestrant

(October 26, 2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast... Continue Reading


Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

(October 23, 2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior... Continue Reading


Flu Shot 101 – What You Need to Know

(October 19, 2017)

Flu season is here again, and besides a fever and runny nose, it can bring about the longtime controversy surrounding vaccines. In order to protect more human lives this year and to clarify some of the most common misconceptions surrounding the flu vaccine,... Continue Reading


FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

(October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading


Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

(October 17, 2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A... Continue Reading


Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

(October 16, 2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients... Continue Reading


Immunotherapy Active Against Triple-Negative Breast Cancer

(October 12, 2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple... Continue Reading


LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

(October 10, 2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition... Continue Reading


« Previous PageNext Page »